South Africa rolls out twice-yearly HIV prevention drug

0

South Africa rolls out twice-yearly HIV prevention drug

South Africa rolls out twice-yearly HIV prevention drug

South Africa rolls out twice-yearly HIV prevention drug

President of South Africa Cyril Ramaphosa, pictured in 2025 at the G20 summit, on Friday announced that the HIV prevention drug Lenacapavir will is now available at medical facilities across the country. File Photo by Jemal Countess/UPI | License Photo

South African officials on Friday announced that the HIV prevention drug Lenacapavir is now available there, calling it “a major turning point” in the nation’s story.

South African President Cyril Ramaphosa said during a launch event in Secunda, South Africa, that starting Friday the drug is available at 360 public health facilities across six provinces and 24 “high-burden districts” as the country aims to reach three million people over the next three years.

Because Lenacapavir is a twice-annual injection, as opposed to other daily oral drugs to prevent HIV, it is easier for many people to adhere to — making it easier to prevent spread of the virus — Gilead, the drug’s manufacturer, has found in phase 3 trials.

“The launch of Lenacapavir marks a turning point in our nation’s fight against HIV,” Ramaphosa said during his remarks.

“To us, Lenacapavir is not just a medicine or a drug,” he said. “To us, it represents a major turning point in South Africa’s national story.”

The launch is the first of several that Gilead has worked on in countries battling HIV that will see local manufacturing of generic versions of the drug to help bring down costs and make it more readily available, the company said in a press release.

South Africa has roughly 7.8 million people living with HIV, and about 170,000 new infections per year — the largest HIV burden in the world — which is why Gilead’s phase 3 trials included many sites there and it is launching the drug there.

“South Africa is at the heart of global efforts to end HIV,” Daniel O’Day, chairman and chief executive officer of Gilead Sciences said in the release.

“With the country’s launch of lenacapavir, there is now an opportunity to rapidly accelerate progress,” O’Day said.

Ramaphosa noted that the rollout is also part of South Africa’s growing pharmaceutical and biotechnology sectors, which is part of the country’s work to pursue the African Union’s goal for 60% of the continent’s health products to be produced there by 2040.

This week in Washington

South Africa rolls out twice-yearly HIV prevention drug

President Donald Trump discusses renovations to the Lincoln Reflecting Pool and makes an announcement on coal in the Oval Office at the White House on Thursday. Photo by Samuel Corum/UPI | License Photo

Source

Leave A Reply

Your email address will not be published.